Corcept Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
16
Price Target
$29.50
Consensus
Outperform
Upside
21.30%
Analysts
0
Stock Rating
16
Upside
21.30%
Analysts
0
Price Target
$29.50

Corcept Therapeutics Stock Forecast and Price Target

If Corcept Therapeutics's stock price reached the average yearlong target of $29.50 given by well-known analysts in recent months, there would be a potential upside of approximately 21.3% from its last closing price in February, 2023. This potential increase is based on a high estimate of $35.00 and a low estimate of $16.00. If you are interested in CORT stock, it is important to also consider its competitors.

$29.50

21.30% Upside

Outperform
Outperform

Corcept Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Corcept Therapeutics's Price has grown by 9.17%, rising from $19.05 to $20.80. 0 analysts predict Corcept Therapeutics's Fair Value will decrease by 3.40% in the next year, reaching $20.09. By 2030, professionals predict that Corcept Therapeutics's Fair Value will decrease by 3.16%, to $20.14.

2022 Fair Value Forecast
$20.09
2023 Fair Value Forecast
$19.76
2024 Fair Value Forecast
$19.99
2025 Fair Value Forecast
$20.26
2026 Fair Value Forecast
$20.21
2027 Fair Value Forecast
$20.06
2028 Fair Value Forecast
$20.04
2029 Fair Value Forecast
$20.11
2030 Fair Value Forecast
$20.14

Corcept Therapeutics Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Corcept Therapeutics's Revenue has grown by 19.41%, rising from $306.49M to $365.98M. 0 analysts predict Corcept Therapeutics's Revenue will decrease by 6.67% in the next year, reaching $341.57M. By 2030, professionals predict that Corcept Therapeutics's Revenue will decrease by 6.09%, to $343.68M.

2022 Rev Forecast
$0.34B
2023 Rev Forecast
$0.33B
2024 Rev Forecast
$0.34B
2025 Rev Forecast
$0.35B
2026 Rev Forecast
$0.35B
2027 Rev Forecast
$0.34B
2028 Rev Forecast
$0.34B
2029 Rev Forecast
$0.34B
2030 Rev Forecast
$0.34B

Corcept Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

Corcept Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

Corcept Therapeutics's Free Cash Flow has seen impressive growth In the last two years, rising from $135.03M to $166.65M – a growth of 23.42%. The next year, 0 experts forecast that Corcept Therapeutics's Free Cash Flow will decrease by 9.84%, reaching $150.25M. In 2030, professionals predict that Corcept Therapeutics's Free Cash Flow will decrease by 8.97%, reaching $151.70M.

2022 FCF Forecast
$0.15B
2023 FCF Forecast
$0.15B
2024 FCF Forecast
$0.15B
2025 FCF Forecast
$0.15B
2026 FCF Forecast
$0.15B
2027 FCF Forecast
$0.15B
2028 FCF Forecast
$0.15B
2029 FCF Forecast
$0.15B
2030 FCF Forecast
$0.15B

Corcept Therapeutics Net Income Forecast for 2023 - 2025 - 2030

Corcept Therapeutics's Net Income has grown In the last two years, rising from $94.18M to $112.51M – a growth of 19.46%. In the following year, the 0 analysts surveyed believe that Corcept Therapeutics's Net Income will decrease by 7.57%, reaching $103.99M. According to professionals, by 2030, Corcept Therapeutics's Net Income will have decreased by 6.94%, falling down to $104.70M.

2022 NI Forecast
$0.10B
2023 NI Forecast
$0.10B
2024 NI Forecast
$0.10B
2025 NI Forecast
$0.11B
2026 NI Forecast
$0.11B
2027 NI Forecast
$0.10B
2028 NI Forecast
$0.10B
2029 NI Forecast
$0.10B
2030 NI Forecast
$0.10B

Corcept Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Corcept Therapeutics's EBITDA has grown by 11.79%, rising from $112.31M to $125.55M. According to the 0 analysts polled, in the next year, Corcept Therapeutics's EBITDA will fall by 2.57%, reaching $122.33M. By 2030, professionals believe that Corcept Therapeutics's EBITDA will have decreased by 2.30%, falling to $122.66M.

2022 EBITDA Forecast
$0.12B
2023 EBITDA Forecast
$0.12B
2024 EBITDA Forecast
$0.12B
2025 EBITDA Forecast
$0.12B
2026 EBITDA Forecast
$0.12B
2027 EBITDA Forecast
$0.12B
2028 EBITDA Forecast
$0.12B
2029 EBITDA Forecast
$0.12B
2030 EBITDA Forecast
$0.12B

Corcept Therapeutics EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Corcept Therapeutics's EBIT has grown, moving from $111.61M to $124.48M – an increase of 11.53%. For the next year, 0 analysts project Corcept Therapeutics's EBIT to drop by 2.32%, reaching $121.59M. By 2030, professionals believe that Corcept Therapeutics's EBIT will decrease by 2.05%, reaching $121.92M – a concerning trend for the company.

2022 EBIT Forecast
$0.12B
2023 EBIT Forecast
$0.12B
2024 EBIT Forecast
$0.12B
2025 EBIT Forecast
$0.12B
2026 EBIT Forecast
$0.12B
2027 EBIT Forecast
$0.12B
2028 EBIT Forecast
$0.12B
2029 EBIT Forecast
$0.12B
2030 EBIT Forecast
$0.12B

Corcept Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Corcept Therapeutics's EPS has grown by 9.17%, rising from $1.09 to $1.19. 0 analysts predict Corcept Therapeutics's EPS will decrease by 3.40% in the next year, reaching $1.15. By 2030, professionals predict that Corcept Therapeutics's EPS will decrease by 3.16%, to $1.15.

2022 EPS Forecast
$1.15
2023 EPS Forecast
$1.13
2024 EPS Forecast
$1.14
2025 EPS Forecast
$1.16
2026 EPS Forecast
$1.16
2027 EPS Forecast
$1.15
2028 EPS Forecast
$1.15
2029 EPS Forecast
$1.15
2030 EPS Forecast
$1.15